The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors

Sonja Stieb a,⇑, Ismael Perez-Martinez a, Abdallah S.R. Mohamed a, Stockton Rock a, Nimit Bajaj a, Tanaya S. Deshpande a, Mohamed Zaid a, Adam S. Garden a, Ryan P. Goepfert b, Richard Cardoso b, Renata Ferrarotto c, Jay P. Reddy a, Jack Phan a, William H. Morrison a, David I. Rosenthal a, Eugene J. Koaya a, Steven J. Frank a, C. David Fuller a, G. Brandon Gunn a, MD Anderson Head and Neck Cancer Symptom Working Group

a Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
b Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
c Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

Article info

Article history:
Received 3 April 2020
Revised 27 May 2020
Accepted 29 May 2020
Available online 9 June 2020

Keywords:
Head and neck neoplasms
Oropharyngeal cancer
Radiotherapy
Stents
Immobilization
Quality of life
Oral health
Taste
Xerostomia
Dysphagia

A B S T R A C T

Objectives: To evaluate whether the use of oral stents during intensity modulated radiation therapy (IMRT) for oropharyngeal cancer (OPC) is associated with long-term patient reported symptoms.

Materials and methods: Data was obtained from a prospective observational study of disease-free head and neck cancer survivors. Radiation-associated patient reported symptoms were assessed using the MD Anderson Symptom Inventory Head and Neck module (MDASI-HN). Scores of >5 (11-point Likert scale, 0-10) were considered moderate/severe. Stratification was performed regarding IMRT volume (uni- versus bilateral neck) and stent utilization, with non-parametric analyses between groups.

Results: 462 OPC survivors formed the cohort (54% tonsil, 46% base of tongue primaries). A tongue-deviating stent was used in 17%, tongue-depressing stent in 46%, and no stent in 37%. Median prescribed dose to the high dose clinical target volume was 66.0 Gy. Median follow-up from RT to MDASI-HN assessment was 68 months. Twenty percent had received unilateral neck RT (all had tonsil primaries), in whom a significant improvement in the proportion of patients with moderate/severe taste impairment (2% vs. 15%, p = 0.047) and lack of appetite (0% vs. 9%, p = 0.019) was associated with the use of tongue-deviating stents compared to no oral stent. In those who had received bilateral neck RT, a significant improvement in the proportion of patients with moderate/severe difficulty swallowing/chewing was associated with use of a tongue-depressing stent (21% vs. 31% without oral stent, p = 0.013).

Conclusion: Disease-site specific select use of oral stents during IMRT was associated with reduced long-term patient reported symptoms in OPC survivors.

© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Xerostomia, taste impairment, and dysphagia are common late radiation-associated side effects that can negatively impact the quality of life of head and neck cancer (HNC) survivors [1–3], and the severity of these oral-related toxicities has been shown to be related in part to radiotherapy (RT) dose delivered to the oral tongue and its associated mucosa, salivary glands, and musculature [4–6].

Oral stents can be used during RT for oropharyngeal cancer (OPC) to better position the oral tissues to facilitate normal tissue sparing and/or immobilize the tongue. For example, tongue-deviating oral stents can be used to displace the non-target oral tongue away from the target volume, such as in well-lateralized tonsil cancers treated with unilateral neck RT. Tongue-depressing oral stents can be used in base of tongue (BOT) cancers to displace the BOT target volume away from the non-target palate and help to
immobilize the tongue to facilitate tongue/target position reproducibility [7] and accurate RT delivery.

While patient-specific custom oral stents, fabricated by our dental oncologists, are commonly used at our center for the treatment of OPC based on the aforementioned rationale and the demonstrated dosimetric advantages [8–14], the use of custom oral stents may not be routinely used in many radiation oncology practices owing to availability of dental expertise/resources or lack of studies demonstrating clinical benefit in terms of late toxicity reduction. In recent years, pre-fabricated commercial stent products became available and stent fabrication became easier and less time consuming with the innovation of 3D printers [15–17]. However, 3D printers in hospitals are still not common devices.

As part of an ongoing effort by our MD Anderson Head and Neck Cancer Symptom Working Group to profile patient reported symptoms and outcomes in HNC survivors and to advance clinical practice by developing strategies to reduce RT-associated toxicities, the specific aim of the present study was to assess whether the use of oral stents is associated with oral morbidity-related patient reported symptoms in OPC survivors after treatment with intensity modulated radiation therapy (IMRT).

2. Material and methods

2.1. Study procedure

Adult HNC patients who had received RT with curative intent, who were without evidence of active disease and had completed initial therapy more than 6 months previously were eligible to participate in an Institutional Review Board (IRB)-approved, single institution, prospective longitudinal symptom assessment study. Study-specific informed consent was provided by all participants, who then either self-completed patient reported outcome questionnaires via pencil/paper during follow-up visit or via telephone interview conducted by study personnel using a study-specific IRB-approved script.

The current study is based on a cross-sectional sample of the aforementioned study using the validated MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN) [18]. In the current study we analyzed six potentially oral morbidity-related items of the MDASI-HN completed at a minimum of 12 months after completion of IMRT (including volumetric arc radiation therapy [VMAT]) for treatment of tonsil or BOT squamous cell carcinoma. These items were: problem tasting food, dry mouth, mucus in mouth/throat, difficulty swallowing/chewing, mouth/throat sores, and lack of appetite.

Since the patients' symptoms had been assessed at various time points in the post-RT follow-up period with the MDASI-HN, we used the last assessment for our analysis in patients who had no cancer events subsequent to treatment. The last MDASI-HN has been chosen, as our group previously showed, that even after years from RT there is still potential for improvement of late radiation-associated symptoms like taste impairment [19]. For patients who developed local/regional recurrence, received systemic therapy for distant metastases or second malignancy, or had oral surgery in the follow-up period, we used the last MDASI before this event or otherwise excluded the patient if this MDASI was...
completed within the first year post-RT (Suppl. Table 1). Patients excluded from this analysis were those with missing information regarding oral immobilization.

The symptom items are rated by patients on an 11-point Likert scale from 0 (“not present”) to 10 (“as bad as you can imagine”), indicating the presence and severity of the symptoms over the past 24 hours. Symptom ratings were considered mild with a score of 1–4, moderate 5–6 and severe 7–10. Patient demographics and tumor and treatment characteristics were extracted from the electronic medical record. Tumor category is described according to tumor and treatment characteristics were extracted from the electronic medical record. Tumor category is described according to the current cancer staging manual of the American Joint Committee on Cancer (AJCC) at the time of the initial diagnosis.

2.2. Patient treatment

All patients had undergone CT simulation and were immobilized for simulation and treatment using a customized thermoplastic head, neck and shoulder mask with or without a customized oral stent at the discretion of the treating radiation oncologist. Use of stent was considered for patients who could safely and reliably tolerate stent use and achieve oral immobilization and/or displacement. A customized mouth-opening and tongue-depressing oral stent was generally used for patients with BOT primaries and a tongue-deviating oral stent for patients with small tonsil primaries or those confined to the tonsillar fossa (Fig. 1).

All patients had received IMRT (or VMAT) with 6 MV photons. Patients with well-lateralized T1-T2 tonsil primaries without evidence of contralateral nodal disease were generally treated with unilateral neck RT [20]; all others were generally treated with bilateral neck RT.

2.3. Statistical analysis

All statistical analyses were performed with IBM SPSS Statistics 24 (IBM, Armonk, NY) and JMP Pro 14 (SAS Institute, Cary, NC). Descriptive statistics were used for description of patient population and symptom ratings. Mann-Whitney U and Kruskal-Wallis test were performed for non-parametric group comparison analyses. Spearman rho test was applied to test for correlation between symptoms. Univariate analysis was used for selection of confounding factors on symptoms (no/mild vs. moderate/severe), which were then investigated in the multivariate analysis if more than one factor had a p-value below 0.1 (both nominal logistic regression). A non-Bonferroni corrected p-value of <0.05 was considered as significant for this hypothesis generating study.

3. Results

Four hundred sixty-two OPC survivors formed the cohort. Eighty-three percent were male, 17% female, with a median age of 55 years. The median follow-up from end of RT (2001–2015) to MDASI-HN assessment (collected from 2010 to 2019) was 68 months (range 13–158).

Two hundred forty-eight patients (54%) had tonsil primaries and 214 (46%) BOT. Most had T1 (36%) – T2 (39%) tumors and 91% were node positive. The most common radiation treatment fractionation schedules were 66 Gy in 30 fractions (48%), and 70 Gy in 33 fractions (36%). Chemotherapy was used in 45% of patients (including induction, concurrent and/or adjuvant chemotherapy) and 13% received concurrent targeted therapy. Details of the patient population are displayed in Table 1.

Unilateral neck RT was delivered in 94 patients with tonsil cancer (20% of the whole cohort; 38% of the tonsil cancer patients). In these, 49 (53%) were treated with a tongue-deviating stent. Bilateral RT was received by 364 patients; 152 with tonsil cancer (20% of them with tongue-deviating stent, 16% with tongue-depressing stent) and 212 with BOT primary (85% with tongue-depressing stent) (Suppl. Table 1).

3.1. Long-term patient reported symptoms

The topmost severe symptom was dry mouth (mean rating: 3.89), followed by difficulty swallowing/chewing (2.70), mucus in mouth/throat (2.15), problem tasting food (1.82), lack of appetite (0.90) and mouth/throat sores (0.49) (Suppl. Table 2). Moderate/severe symptom ratings were reported by 39% of the patients for dry mouth, 24% for difficulty swallowing/chewing, 19% for mucus in mouth/throat and 16% for problem tasting food; the percentage of patients with moderate/severe ratings for lack of appetite and mouth/throat sores was less than 10% (Fig. 2, Suppl. Table 2). There

---

Table 1

| Table 1 | Patient and treatment characteristics of the study cohort (n = 462 patients). |
|---------|--------------------------------------------------------------------------------------------------|
|         | Sex  | n (%)* |
|---------|------|--------|
| Male    | 385  | (83.3%)|
| Female  | 77   | (16.7%)|
| Age at RT start [years] | Mean/SD | Median | Range |
|---------|------|--------|-------|
| Mean    | 56   | 55     | 29–84 |
| Race    |      |        |       |
| Caucasian | 448 | (97.0%)|      |
| Asian   | 3    | (0.6%)  |      |
| Black or African American | 7 | (1.5%) |      |
| American Indian or Alaska Native | 2 | (0.4%) |      |
| Unavailable | 2 | (0.4%) |      |
| Primary tumor site | |        |       |
| Tonsil | 248 | (53.7%)|      |
| BOT    | 214 | (46.3%)|      |
| Tumor category | |        |       |
| Tis    | 1 | (0.2%) |      |
| T1     | 168 | (36.4%)|      |
| T2     | 181 | (39.2%)|      |
| T3     | 72  | (15.6%)|      |
| T4     | 35  | (7.6%)  |      |
| Nodal status | |        |       |
| N0    | 40  | (8.7%)  |      |
| N+    | 422 | (91.3%)|      |
| N+    | 422 | (91.3%)|      |
| Tumor HPV or p16 | |        |       |
| Positive | 222 | (48.0%)|      |
| Negative | 22  | (4.8%)  |      |
| Unknown | 218 | (47.2%)|      |
| PTV1 [Gy] | |        |       |
| Mean/SD | 67.9 | (2.4)  |      |
| Median | 66   |        |       |
| Range  | 57.6–72.5 |      |       |
| Number of fractions | |        |       |
| Mean/SD | 31.9 | (2.6)  |      |
| Median | 30   |        |       |
| Range  | 27–40 |      |       |
| Chemotherapy | |        |       |
| Any    | 256  | (44.6%)|      |
| Induction | 152 | (32.9%)|      |
| Concurrent | 156 | (33.8%)|      |
| Adjuvant | 5  | (1.1%)  |      |
| Targeted therapy | |        |       |
| Concurrent | 58 | (12.6%)|      |
| Smoking status at RT start | |        |       |
| Current smoker | 31 | (6.7%) |      |
| Former smoker | 173 | (37.4%)|      |
| Never smoker | 204 | (44.2%)|      |
| Unavailable | 54 | (11.7%)|      |

*If not indicated otherwise; BOT: base of tongue, PTV1: high dose planning target volume, n: number of patients, N+: node positive, RT: radiotherapy, SD: standard deviation
was a highly significant correlation between all symptoms analyzed \((p < 0.001)\) (Suppl. Table 3).

### 3.2. Effect of radiation technique

Patients with T1–2 tonsil cancer treated with unilateral neck RT had lower mean MDASI-HN scores compared to patients treated bilaterally for all the reported symptoms except for mouth/throat sores (Suppl. Table 4).

For problem tasting food, mouth/throat mucus, and lack of appetite, about half as many patients reported moderate/severe ratings treated with unilateral vs. bilateral neck RT (6.5 vs. 15.0%, 8.3% vs. 17.5%, 3.1 vs. 9.2%; respectively, Suppl. Table 4).

### 3.3. Effect of oral stent

For those patients who received unilateral neck RT, there was a significant difference in the number of patients in the different MDASI-HN categories (no, mild, moderate, severe) for taste impairment when comparing patients with tongue-deviating stent versus no stent \((p = 0.047, \text{Fig. 3})\). Thirteen percent of patients treated without stent reported severe taste impairment whereas no patient treated with a tongue-deviating stent had severe problems tasting food. The mean MDASI-HN score for taste was 0.51 versus 1.74 in patients with and without stent, respectively (Table 2). Appetite was also significantly better in patients treated with a tongue-deviating stent (Table 2, Fig. 3). Both symptoms, taste impairment and lack of appetite, were significantly less with the oral stent when comparing the groups with no/mild versus moderate/severe symptoms (taste impairment: \(p = 0.027\), lack of appetite: \(p = 0.030\)). Patients with a tongue-deviating stent had significantly earlier T-category than patients without stent (T1: 79% vs. 59%, respectively, Suppl. Table 5), but when subgrouping by T-category (T1 and T2) lower MDASI-HN taste impairment and lack of appetite scores for each stage were still observed (Suppl. Table 6).

One hundred eighty patients (88%) with BOT cancers were treated with bilateral RT and a tongue-depressing stent compared with only 25 patients (12%) with tonsillar cancer \((p < 0.001, \text{Suppl. Table 5})\).

Patients with bilateral radiotherapy treated with a tongue-depressing stent reported significantly less swallowing/chewing difficulty and fewer mouth/throat sores (Table 2): Ten percent of patients treated with a tongue-depressing stent reported severe dysphagia after therapy, compared to 18% treated without an oral stent \((p = 0.013\) for comparison of the severity categories). Regarding mouth/throat sores, 84% of patients had no symptoms if treated with a tongue-depressing stent compared to 75% of patients treated without a stent \((p = 0.028\) for comparison of the severity categories). When the symptom severity groups were merged together to no/mild versus moderate/severe toxicity, swallowing/chewing difficulty remained significantly different between patients treated with or without stent \((p = 0.049)\).

### 3.4. Multivariate analysis of patient and treatment factors on oral morbidity-related symptoms

The use of a stent was significantly associated with lower taste impairment, difficulty swallowing/chewing and lack of appetite in patients irradiated with unilateral radiotherapy in univariate analysis and remained significant for taste and appetite in multivariate analysis (Table 3).

In patients irradiated with bilateral neck RT, current smoking at RT start had a significant negative influence on all oral morbidity-related symptoms (no/mild vs. moderate/severe). Positive lymph node status was associated with increased taste impairment in these patients (Table 3).
4. Discussion

The dosimetric advantage of different oral stent types as well as the “stick-out” tongue technique for HNC RT has already been described in other studies [8–14,21] (Table 4). To our knowledge, this study of over 450 patients with OPC and long-term survival is the first to attempt to translate these dosimetric advantages of stent usage into a clinical benefit with regards to decreasing late symptoms in HNC patients. We found both a benefit to a tongue-deviating stent for patients treated with unilateral neck RT, and a tongue-depressing stent for patients treated with bilateral neck RT.

Patients treated with unilateral neck RT with a tongue-deviating oral stent for early tonsil cancer reported lower scores for taste impairment and lack of appetite. Although the difference in mean MDASI-HN score between the groups with and without oral stent might be low, there is a significant decreased proportion of patients who had moderate/severe symptoms. Less toxicity has already been reported for unilateral irradiation in cohorts of OPC [22] and tonsil cancers only [23,24] compared to standard bilateral RT by other authors. Despite these patients having in general a lower toxicity profile, the addition of a tongue-deviating stent further decreases long-term patient reported symptoms.

Patients treated with tongue-depressing stents and bilateral neck RT showed significantly less moderate/severe dysphagia and mouth/throat sores. Besides the overall beneficial effect on long-term toxicity, the tongue-depressing stent has been previously shown to improve patient and oral immobilization during treatment [7]. This improvement in immobilization can lead to an improved image quality in MRI [7], which is often fused with the planning CT for better target and organ at risk delineation. Furthermore, the increased reproducibility of patient positioning during RT may possibly contribute to a higher local tumor control rate. However, that particular study [7] was conducted at baseline, mid-treatment and one month post-treatment only, and not at the end of the treatment when the radiation side effects are most severe, which could negatively impact patient tolerability of the

Table 2

MDASI-HN symptom ratings according to neck RT laterality and stent use. MDASI-HN scores of ≥1 and ≤4 are considered as mild, ≥5 and ≤6 moderate and ≥7 severe symptoms.

|                     | Unilateral radiotherapy | Bilateral radiotherapy |
|---------------------|-------------------------|------------------------|
|                     | MDASI-HN score/ symptom categories | Tongue-deviating stent | No stent | p-value (no vs. tongue-deviating stent) | Tongue-depressing stent | No stent | p-value (no vs. tongue-depressing stent) |
| Number of patients  | 49                      | 43                     | 205      | 129                                   |                       |                      |
| Taste impairment    | Mean/SD                 | 0.51/1.16              | 1.74/3.14| 0.056                                 | 2.20/2.77             | 1.92/2.52            | 0.555                      |
|                     | Median                  | 0                      | 0        |                                       | 1                      | 1                    |
| Range               | 0–5                     | 0–10                   | 0–10     | 0–10                                  | 0–10                   | 0–10                 |
| No                  | 77.10%                  | 62.50%                 | 43.00%   | 43.10%                                | 43.10%                 | 43.10%               | 0.773                      |
| Mild                | 20.80%                  | 22.50%                 | 37.00%   | 39.00%                                | 39.00%                 | 39.00%               |
| Moderate            | 2.10%                   | 2.50%                  | 9.00%    | 10.60%                                | 10.60%                 | 10.60%               |
| Severe              | 0%                      | 12.50%                 | 11.00%   | 7.30%                                 | 7.30%                  | 7.30%                |
| Dry mouth           | Mean/SD                 | 3.08/2.91              | 3.18/3.19| 0.707                                 | 4.20/2.97             | 4.04/2.99            | 0.604                      |
|                     | Median                  | 2                      | 2.5      |                                       | 4                      | 3                    |
| Range               | 0–10                   | 0–10                   | 0–10     | 0–10                                  | 0–10                   | 0–10                 |
| No                  | 18.40%                  | 20.90%                 | 11.20%   | 10.20%                                | 10.20%                 | 10.20%               | 0.747                      |
| Mild                | 55.10%                  | 51.20%                 | 44.40%   | 49.60%                                | 49.60%                 | 49.60%               |
| Moderate            | 12.20%                  | 9.30%                  | 20.50%   | 15.70%                                | 15.70%                 | 15.70%               |
| Severe              | 14.30%                  | 18.60%                 | 23.90%   | 24.40%                                | 24.40%                 | 24.40%               |
| Mucus in mouth/throat | Mean/SD              | 1.54/2.14              | 1.33/2.41| 0.373                                 | 2.25/2.59             | 2.58/2.81            | 0.335                      |
|                     | Median                  | 0                      | 0        |                                       | 1                      | 2                    |
| Range               | 0–9                    | 0–10                   | 0–10     | 0–10                                  | 0–10                   | 0–10                 |
| No                  | 53.10%                  | 62.80%                 | 37.80%   | 33.90%                                | 33.90%                 | 33.90%               | 0.377                      |
| Mild                | 34.70%                  | 30.20%                 | 41.80%   | 42.50%                                | 42.50%                 | 42.50%               |
| Moderate            | 10.20%                  | 0.00%                  | 10.00%   | 10.20%                                | 10.20%                 | 10.20%               |
| Severe              | 2.00%                   | 7.00%                  | 10.40%   | 13.40%                                | 13.40%                 | 13.40%               |
| Difficulty swallowing/ chewing | Mean/SD            | 1.83/2.65              | 2.81/3.04| 0.068                                 | 2.53/2.54             | 3.28/2.78            | 0.013                      |
|                     | Median                  | 1                      | 1.5      |                                       | 2                      | 3                    |
| Range               | 0–10                   | 0–10                   | 0–10     | 0–10                                  | 0–10                   | 0–10                 |
| No                  | 44.90%                  | 30.20%                 | 28.80%   | 19.40%                                | 19.40%                 | 19.40%               | 0.013                      |
| Mild                | 38.80%                  | 41.90%                 | 50.20%   | 50.00%                                | 50.00%                 | 50.00%               |
| Moderate            | 6.10%                   | 16.30%                 | 11.20%   | 12.90%                                | 12.90%                 | 12.90%               |
| Severe              | 10.20%                  | 11.60%                 | 9.80%    | 17.70%                                | 17.70%                 | 17.70%               |
| Mouth/throat sores  | Mean/SD                 | 0.65/1.77              | 0.69/1.63| 0.606                                 | 0.37/1.24             | 0.55/1.26            | 0.023                      |
|                     | Median                  | 0                      | 0        |                                       | 0                      | 0                    |
| Range               | 0–9                    | 0–10                   | 0–8      | 0–7                                   | 0–8                    | 0–7                  |
| No                  | 81.60%                  | 76.70%                 | 84.40%   | 75.00%                                | 75.00%                 | 75.00%               | 0.028                      |
| Mild                | 14.30%                  | 18.60%                 | 11.20%   | 22.70%                                | 22.70%                 | 22.70%               |
| Moderate            | 4.10%                   | 2.30%                  | 2.40%    | 1.60%                                 | 1.60%                  | 1.60%               |
| Severe              | 4.10%                   | 2.30%                  | 1.00%    | 0.80%                                 | 0.80%                  | 0.80%               |
| Lack of appetite    | Mean/SD                 | 0.17/0.66              | 1.02/2.27| 0.018                                 | 0.96/2.05             | 1.12/2.17            | 0.242                      |
|                     | Median                  | 0                      | 0        |                                       | 0                      | 0                    |
| Range               | 0–4                    | 0–10                   | 0–10     | 0–10                                  | 0–10                   | 0–10                 |
| No                  | 91.80%                  | 74.40%                 | 73.60%   | 66.70%                                | 66.70%                 | 66.70%               | 0.199                      |
| Mild                | 8.20%                   | 16.30%                 | 18.90%   | 25.40%                                | 25.40%                 | 25.40%               |
| Moderate            | 0%                      | 4.70%                  | 4.00%    | 2.40%                                 | 2.40%                  | 2.40%               |
| Severe              | 0%                      | 4.70%                  | 3.50%    | 5.60%                                 | 5.60%                  | 5.60%               |

BOT: base of tongue. SD: standard deviation. Significant p-values in bold.
Table 3
Results (p-values) of univariate and multivariate (in brackets) analysis for different radiation-associated symptoms divided into groups with unilateral and bilateral radiation technique. Factors with p-values < 0.1 were included into the multivariate analysis.

|                      | Taste impairment | Dry mouth | Mucus in mouth/throat |
|----------------------|------------------|-----------|-----------------------|
|                      | Unilateral       | Bilateral | Unilateral            | Bilateral | Unilateral       | Bilateral |
| Sex                  | 0.265            | 0.371     | 0.734                 | 0.014 (0.021) | 0.167            | 0.700     |
| Age at RT start      | 0.053 (0.037)    | 0.088 (0.171) | 0.674 | 0.617 | 0.834 | 0.521     |
| Tumor site           | 0.734            | 0.032 (0.024) | 0.858 | 0.143 | 0.040 (0.163) |           |
| N0 vs. N+            | 0.591            | 0.081 (0.129) | 0.890 | 0.124 | 0.160 |           |
| Chemo yes vs. no     | 0.091 (0.085)    | 0.420     | 0.032 (0.024) | 0.017 (0.014) | 0.240            | 0.003 (0.006) |
| Current smoking at RT start | 0.497          | 0.027 (0.016) | 0.429 | 0.240 | 0.003 (0.006) |           |

PTV1: high dose planning target volume, N+: node positive, RT: radiotherapy

Table 4
Overview of published studies investigating oral stents for external beam head and neck radiotherapy.

| Author, year | Available publication | n   | Tumor subsite | Stent type definition | Dosimetric result | Toxicity outcome |
|--------------|-----------------------|-----|---------------|-----------------------|-------------------|------------------|
| Feng, 2019   | Original paper        | 60  | Sinus, gingiva, nasal lymphoma, olfactory neuroblastoma | Bite block | Sign. lower Dmean to the tongue, Dmax to submandibular gland and Dmean to mandible, bilateral PGs and SMGs. No difference for PTV. | 15% G1 mucositis, 10% G2 mucositis during RT; no taste dysfunction or xerostomia (median follow-up 25 months). |
| Grant, 2019  | Conference abstract   | 20  | Tonsil        | Tongue-devating stent | Sign. lower Dmean and V30 to oral mucosa and tongue for IMRT. No difference for IMPT. No difference for both techniques for oral mucosa and tongue D3cc. | – |
| Kil, 2017    | Case report           | 3   | BOT           | “Stick-out” tongue     | Sign. more distance between BOT/PC, tongue/hard palate and gingiva/lips. Sign. reduced Dmean to OC, tongue and lips (only for OPC). Lower V15/V30/V45 of tongue. | – |
| Kil, 2016    | Original paper        | 13  | Tonsil, larynx | Radiation-positioning stent | Sign. less dose to the maxilla in tumors of/near the mandible with stent. Also less dose to the mandible in tumors of/near the maxilla with stent, but not sign. | – |
| Nayar, 2016  | Original paper        | 55  | HNC           | Radiation-positioning stent | Sign. less dose to the maxilla in tumors of/near the mandible with stent. Also less dose to the mandible in tumors of/near the maxilla with stent, but not sign. | Sign. improvement of 78% in mouth-opening with stent 1–2 months post-RT. |
| Verrone, 2014| Original paper        | 33  | Tongue, floor of mouth | Mouth-opening, tongue-depressing stent | Sign. lower Dmean to the maxilla and ipsilateral PG with stent, but PTV dose in this group sign. lower. | Later onset of G3 mucositis with stent during RT. |
| Mall, 2016   | Original paper        | 30  | Posterior tongue | Positioning stent | – | Sign. higher salivary flow rates (stimulated and unstimulated) and sign. better xerostomia-related QoL with stent at 3 and 6 months post-RT. |
| Verrone, 2013| Case report           | 1   | Tongue        | Mouth-opening, tongue-depressing stent | Lower Dmean to teeth, hard palate, PGs, left SMG with stent; target coverage similar. | – |
| Goel, 2010   | Original paper        | 48  | Tongue        | Positional stents       | – | Sign. lower palatal mucositis and xerostomia with stent at 30, 45 and 60 days post-RT. |
Stents. Stent compliance or patient stent experience was not formally assessed as part of this study but would be worthy of future investigation.

A limitation of this study is the non-randomization of stent use and the non-standardization of clinical factors leading to stent use decision-making. Furthermore, due to the eligibility criteria of the parent study including only patients without active disease, any positive or negative association of stent use with local control could not be assessed. However, there is evidence that stent use is beneficial in terms of dosimetric parameters of the organs at risk [8–14,21], and we add data to suggest a clinical benefit with regards to patient reported long-term outcomes. This study is a retrospective analysis of prospectively collected data, and while randomized data is regarded as strongest from a scientific perspective, recognizing stents improve dosimetry with regards to avoidance of normal tissue, and treatment reproducibility, it is moot whether randomized data is an absolute necessity. Another limitation in our study is the wide range of individual MDASI-HN time points after RT. Although we excluded patients with only MDASI-HN assessments within the first 12 months from end of RT, others have shown there is further improvement of oral morbidity-related symptoms over time [25]. However, since the time points of analyzed MDASI-HN assessments did not vary much between the groups with or without stent (Suppl. Table 5), the impact of varying time points are likely at most of minor impact.

5. Conclusions

When safely and reliably tolerated, use of a tongue-deviating stent should be considered for selected tonsil cancer patients when treated with unilateral neck RT as it was significantly associated with improved long-term patient reported taste and appetite. Likewise, our data also suggest the select use of tongue-depressing stents for patients treated with bilateral neck RT for BOT cancers reduced long-term patient reported dysphagia and mouth/throat sores. Routine involvement of dental oncology specialists should be part of the multidisciplinary care of OPC patients.

6. Role of Funding Sources

None of the funding sources had an influence on study design; in the collection, analysis and interpretation of data; in the writing of the manuscript and the decision to submit the article for publication.

Acknowledgement

S. Stieb is funded by the Swiss Cancer League (BIL KLS-4300-08-2017). I. Perez-Martinez was sponsored by the National Institutes of Health’s National Cancer Institute Partnership for Excellence in Cancer Research (U54CA096300/U54CA096297) to perform this research. R. Ferrarotto is advisory board member of Ayala and Regeneron-Sanofi and received consulting fees from Ayala and Celestella and produces educational videos for Medscape. S.J. Frank is a paid consultant/advisory board member for Varian and advisory board member for Hitachi and Breakthrough Chronic Care. He is founder and director of and has received grants and personal fees from C4 Imaging. He reports grants from Eli Lilly, Elekta, grants and honoraria from Hitachi and personal fees from Boston Scientific and the National Comprehensive Cancer Network (NCCN).

C.D. Fuller received funding from the National Institute for Dental and Craniofacial Research Award (R01DE025248-01/R56DE025248) and Academic-Industrial Partnership Award (R01DE028290), the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBDD) Grant (NSF 1557679), the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825), the NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148), the NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P03CA016672), the NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Program (R25EB025787). He has received direct industry grant support, speaking honoraria and travel funding from Elekta AB. G.B. Gunn is supported by a philanthropic donation made by the Family of Paul W. Beach.

Declarations of Competing Interest

The authors declare no conflict of interest.

References

[1] Kakooei S et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 2012;15(4):214–8.
[2] Baharvand M et al. Taste alteration and impact on quality of life after head and neck radiotherapy. J Oral Pathol Med 2013;42(1):106–12.
[3] Nguyen NP et al. Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005;61(3):772–8.
[4] Kamal M et al. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: results of a prospective registry. Radiother Oncol 2018;128(3):442–51.
[5] Chen WC et al. Long-term taste impairment after intensity-modulated radiotherapy to treat head-and-neck cancer: correlations with glossoscopy and the mean radiation dose to the oral cavity. Chem Senses 2019;44(5):319–26.
[6] Beetz I et al. Role of minor salivary glands in developing patient-rated xerostomia and sticky saliva during day and night. Radiother Oncol 2013;109(2):311–6.
[7] Ding Y et al. Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: should standard positioning and immobilization be required for radiation therapy applications?. Pract Radiat Oncol 2015;5(4):e299–308.
[8] Feng Z et al. Construction and clinical evaluation of a new customized bite block used in radiotherapy of head and neck cancer. Cancer Radiother 2019;23(2):125–31.

[9] Grant S, et al. A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue Deviating Oral Stents. International Journal of Radiation Oncology*Biology*Physics, 2019. 103(5).

[10] Kil WJ et al. Tongue-out versus tongue-in position during intensity-modulated radiotherapy for base of tongue cancer: clinical implications for minimizing post-radiotherapy swallowing dysfunction. Head Neck 2017;39(8):E83–91.

[11] Kil WJ et al. Decreased radiation doses to tongue with “stick-out” tongue position over neutral tongue position in head and neck cancer patients who refused or could not tolerate an intraoral device (bite-block, tongue blade, or mouthpiece) due to trismus, gag reflex, or discomfort during intensity-modulated radiation therapy. Oncotarget 2016;7(33):53029–36.

[12] Nayar S et al. The effect of a Radiation Positioning Stent (RPS) in the reduction of radiation dosage to the opposing jaw and maintenance of mouth opening after radiation therapy. Eur J Prosthodont Restor Dent 2016;24(2):71–7.

[13] Verrone JR et al. Benefits of an intraoral stent in decreasing the irradiation dose to oral healthy tissue: dosimetric and clinical features. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118(5):573–8.

[14] Qin WJ et al. Sparing normal oral tissues with individual dental stent in radiotherapy for primary nasopharyngeal carcinoma patients. Ai Zheng 2007;26(3):285–9.

[15] Zaid M et al. A prospective trial evaluating patient reported outcomes of customized oral stents for Head and Neck (HN) Radiotherapy (RT) using 3D printing and traditional methods. Int J Radiat Oncol Biol Phys 2019;103(5):E35–6.

[16] Zaid M et al. Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiat Oncol 2019;14(1):148.

[17] Wilke CT et al. Design and fabrication of a 3D–printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017. 3(1): p. 12.

[18] Rosenthal DI et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007;29(10):923–31.

[19] Stieb S et al. Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: potential for improvement over time?. Clin Transl Radiat Oncol 2020;22:98–105.

[20] Chronowski GM et al. Unilateral radiotherapy for the treatment of tonsillar cancer. Int J Radiat Oncol Biol Phys 2012;83(1):204–9.

[21] Verrone JR et al. Impact of intraoral stent on the side effects of radiotherapy for oral cancer. Head Neck 2013;35(7):E213–7.

[22] Jensen K, Overgaard M, Grau C. Morbidity after ipsilateral radiotherapy for oropharyngeal cancer. Radiother Oncol 2007;85(1):90–7.

[23] Kim Y et al. Comparison of the clinical outcomes of patients with squamous cell carcinoma of the tonsil receiving postoperative Ipsilateral versus bilateral neck radiotherapy: a propensity score matching analysis (KROG 11–07). Cancer Res Treat 2017;49(4):1097–105.

[24] Chin RI et al. Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. Cancer 2017;123(23):4594–607.

[25] O’Neill M et al. Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. Am J Clin Oncol 2011;34(5):478–82.

[26] Mall P et al. Effectiveness of positioning stents in radiation-induced Xerostomia in patients with tongue carcinoma: a randomized controlled trial. Int J Prosthodont 2016;29(5):455–60.

[27] Goel A et al. Use of positioning stents in lingual carcinoma patients subjected to radiotherapy. Int J Prosthodont 2010;23(3):450–2.